Please ensure Javascript is enabled for purposes of website accessibility

Forget Bitcoin: 4 Stocks to Buy Hand Over Fist Instead

By Sean Williams - Feb 21, 2021 at 5:36AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These growth stocks should trounce the world's largest cryptocurrency over the long run.

For nearly 11 months, the stock market's three major indexes have been virtually unstoppable. Since the March 23 bear market low, the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite are up a cool 70%, 76%, and 104%, respectively.

Yet, on a combined basis, these major indexes don't even come close to matching the 672% return of cryptocurrency giant Bitcoin (BTC 0.92%) over the same time frame.

A physical gold Bitcoin stood on its side in front of a digital chart with volume data.

Image source: Getty Images.

Ignoring the Bitcoin hype would be a smart move

Many of the same theses that bulls have extolled for years continue to drive Bitcoin's ascent. For example, fans still view its 21 million token limit as a hedge against the long-term devaluation of the U.S. dollar as the money supply increases.

Enthusiasts also still value Bitcoin for its payment potential. A greater number of businesses are accepting cryptocurrency now than ever before, and Bitcoin's network can settle payment transactions in an average of 10 minutes. This compares to cross-border payments on traditional networks, which can take up to a week to be validated and settled.

The world's most popular digital currency has also received a boost from brand-name enterprise adoption. Electric-vehicle maker Tesla recently announced a $1.5 billion purchase of Bitcoin, which will be added to the automaker's balance sheet.

But you might be disappointed if you dig beyond the short-term cheerleading and technical analysis. History is clear that when next-big-thing investments go parabolic, they eventually implode. Furthermore, Bitcoin is full of flaws and misconceptions perpetuated on social media platforms.

These high-growth stocks are all better buys than Bitcoin

Rather than putting your hard-earned money to work on an asset that doesn't seem to have any true utility or sustainable advantages, consider the following four growth stocks, all of which have tangible long-term growth prospects.

A key inside of a lock that's surrounded by dozens of alphanumeric codes.

Image source: Getty Images.

CrowdStrike Holdings

Though it may not be the fastest-growing trend this decade, there's a good chance cybersecurity will be the safest double-digit growth opportunity. As businesses continue to shift online and into the cloud, the onus of protecting company and consumer information will fall on third-party providers. That's where CrowdStrike Holdings (CRWD 5.77%) comes in.

CrowdStrike's selling point is its cloud-native Falcon platform, which oversees over 3 trillion events each week. Falcon relies on artificial intelligence to improve at identifying and responding to threats. Because it was built entirely in the cloud, Falcon is more nimble than on-premises security options. Interestingly, it's also cheaper.

The fact of the matter is that CrowdStrike's clients love the product. Over the past 3.5 years, the percentage of customers with at least four cloud module subscriptions has grown from 9% to 61%. This tells us that CrowdStrike's platform is easily scalable to its clients' needs.

What's more, CrowdStrike has just scratched the surface of its addressable market ($32.4 billion, as of fiscal 2021), and it's already reached its long-term subscription gross margin target of between 75% and 80%. It's a fast-paced business you can buy into with confidence. 

A cannabis leaf laid atop a one hundred dollar bill, with Ben Franklin's eyes peering between the leaves.

Image source: Getty Images.

Cresco Labs

Another high-growth stock to buy hand over fist instead of Bitcoin is marijuana stock Cresco Labs (CRLBF 1.09%).

Many investors are pounding the table on pot stocks because they think a Democrat-led Congress will legalize marijuana at the federal level. That's far from a given considering how little our country's two political parties agree on. It's also worth noting that President Joe Biden has only pledged to decriminalize and reschedule cannabis. Thankfully, legalization isn't necessary for a handful of multistate operators to shine, and Cresco is part of that group.

Following the completion of the Verdant Creations acquisition, which added four dispensaries in Ohio, the company has two dozen operating retail locations. Cresco has been particular in targeting limited license states like Illinois and Ohio. With a predetermined number of licenses being issued, it should be able to effectively build up its brand and secure meaningful market share in potentially billion-dollar markets. 

Even more exciting is Cresco's wholesale operations. The company holds one of only a handful of cannabis distribution licenses in California, the largest pot market in the world by annual sales. This gives it the ability to place marijuana products into more than 575 dispensaries throughout the Golden State. Even though wholesale margins aren't as high as retail, Cresco is generating more than enough volume from wholesale to make it a highly lucrative venture.

A dropper placing liquid into a narrow test tube.

Image source: Getty Images.

Vertex Pharmaceuticals

Profitable biotech stocks can put a lot of money in the pockets of patient investors. That's why specialty drug developer Vertex Pharmaceuticals (VRTX 3.19%) would be a much smarter buy than Bitcoin.

What makes Vertex so special is the company's overwhelming success in treating cystic fibrosis (CF), a genetic disorder characterized by thick mucus production that can obstruct the lungs and pancreas. CF has no cure, but Vertex has developed multiple generations of gene-specific CF treatments that have improved quality of life for patients.

The latest development, Trikafta, is a combination therapy that easily met its primary endpoint in phase 3 clinical studies and was approved by the U.S. Food and Drug Administration five months ahead of its scheduled review date. In its first full year on pharmacy shelves in the U.S. and Europe, it brought in nearly $3.9 billion in net sales. Wall Street believes it will generate $6 billion annually in sales, but this might prove to be a conservative estimate

Vertex is also sitting on a mountain of cash, thanks in part to the high margins associated with selling brand-name therapies. It ended the year with $6.7 billion in cash and is likely to use some of this capital to go shopping. While it already has a half-dozen other treatments in development, expanding its portfolio beyond CF would be a smart idea.

A smiling young retail worker using a touchscreen point-of-sale interface at the checkout counter.

Image source: Getty Images.


Finally, ignore Bitcoin and pound the table on cloud-based customer relationship management (CRM) solutions kingpin (CRM 7.44%).

In simple terms, CRM software helps consumer-facing businesses grow. It can be used for everything from simple tasks like logging client information to more complex tasks like managing a marketing campaign or suggesting new products to existing clients. The retail and services industries are obvious CRM software beneficiaries. However, healthcare, manufacturing, and financial businesses can often also benefit from CRM solutions.

When it comes to cloud-based CRM software, every other business looks up to Salesforce as the Goliath. According to IDC, Salesforce controlled just shy of 20% of the global CRM revenue share in the first half of 2020. That's more than its four closest competitors combined. No tea leaves are needed to see that Salesforce is the go-to in this double-digit opportunity

Salesforce is also in the process of acquiring enterprise communications platform Slack Technologies in a $27.7 billion cash-and-stock deal. Assuming it gets the green light, Slack's platform will provide Salesforce with an opportunity to cross-sell its products, much in the same way Microsoft uses Teams as a jumping-off point for its CRM solutions.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Salesforce, Inc. Stock Quote
Salesforce, Inc.
$185.92 (7.44%) $12.87
Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
$292.55 (3.19%) $9.05
Cresco Labs Inc. Stock Quote
Cresco Labs Inc.
$2.79 (1.09%) $0.03
CrowdStrike Holdings, Inc. Stock Quote
CrowdStrike Holdings, Inc.
$184.99 (5.77%) $10.09
Bitcoin Stock Quote
$21,241.54 (0.92%) $194.44

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.